secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2026-10-21T10:15:14+00:00
Accession:  0000917520-26-000073
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Integra Q3 revenue $411.2M (+2.3%), adjusted EPS $0.59; Q4 guide implies revenue decline
--------------------------------------------------------------------------------

- Revenue $411.2M, up 2.3% reported and 2.5% organic, including ~$7M hit from Cincinnati flood damage; GAAP EPS $0.19 vs $(0.07), adjusted EPS $0.59 vs $0.54.
- Specialty Surgery revenue $304.1M (+3.9% reported, +4.2% organic) with Neuro +6.5% organic, Instruments -0.9%, ENT -1.1%; Tissue Reconstruction $107.1M, down 2.2% organic.
- Adjusted gross margin 61.1% vs 62.9%; adjusted EBITDA $79.8M (19.4% of revenue) vs $78.5M; operating cash flow $96.0M; net debt $1.5B; total leverage 3.8x.
- Oct 19 closed $2.1B refinancing: $1.65B credit facility ($600M Term Loan A, $600M revolver, $450M Term Loan B) plus $450M 9.5% notes due 2033; 2027 leverage covenant eased to 4.25x from 4.0x.
- Q4 guide: revenue $413-433M (-5.2% to -0.5%) and adjusted EPS $0.61-0.71; FY26 revenue $1.634-1.654B, adjusted EPS $2.30-2.40, cash flow ~$190-200M, unchanged from Oct 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000073/0000917520-26-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752026000073/iart-20261021.htm
  HTML page:      https://secwatch.observer/filing/0000917520-26-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer